
Novartis Signs $3.2B Alteogen Deal
Novartis has partnered with South Koreas Alteogen in a licensing agreement worth up to $3.22 billion. The deal provides access to technology that converts intravenous treatments into convenient subcutaneous injections.
Xurve View
Insights:
Xurve View

ALTEOGEN INC signed a licensing deal worth up to $3.22 billion with NOVARTIS AG-REG on Wednesday morning, granting the Swiss drugmaker access to subcutaneous drug delivery technology. The agreement represents Alteogen's fourth major partnership of the year, underscoring rising demand for under-the-skin administration. Drug developers increasingly favor subcutaneous injections over traditional intravenous infusions to improve patient convenience.










